30235-28-0

Basic information

• Product Name: 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE
• Synonyms: 2-AMINO-4-(4-PYRIDYL)THIAZOLE;4-PYRIDIN-4-YL-1,3-THIAZOL-2-AMINE;4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE;4-(4-PYRIDINYL)-1,3-THIAZOL-2-YLAMINE;IFLAB-BB F0537-0969;BUTTPARK 37\12-54;2-Amino-4-pyridin-4-yl-1,3-thiazole;4-(4-PYRIDINYL)-2-THIAZOLAMINE
• CAS NO: 30235-28-0
• Molecular Formula: C₈H₇N₃S
• Molecular Weight: 177.23
• Product Categories: Amines;Thiazoles, Isothiazoles & Benzothiazoles
• Mol File: 30235-28-0.mol
• Article Data: 18

Chemical Properties

• Melting Point: 270-272 °C
• Boiling Point: 378.9 °C at 760 mmHg
• Flash Point: 183 °C
• Appearance: /
• Density: 1.333 g/cm³
• Refractive Index: 1.67
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.89±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE(30235-28-0)
• EPA Substance Registry System: 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE(30235-28-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-41-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 30235-28-0(Hazardous Substances Data)

Usage

Description

4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE is a synthetic intermediate that plays a crucial role in pharmaceutical synthesis. It is a chemical compound characterized by its unique structure, which consists of a pyridine ring fused to a thiazole ring with an amine group attached to the thiazole. 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE is known for its potential applications in the development of various pharmaceutical products.

Uses

Used in Pharmaceutical Industry:
4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE is used as a synthetic intermediate for the development of pharmaceutical products. Its unique structure and properties make it a valuable component in the synthesis of various drugs, particularly those targeting specific biological pathways or receptors.
As a synthetic intermediate, 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE can be incorporated into the molecular structure of new drugs, enhancing their efficacy, selectivity, and pharmacokinetic properties. This allows researchers and pharmaceutical companies to develop innovative treatments for a wide range of diseases and conditions.
In addition to its role in drug synthesis, 4-PYRIDIN-4-YL-THIAZOL-2-YLAMINE may also have potential applications in other areas of the pharmaceutical industry, such as drug delivery systems or as a component in the development of prodrugs. Its versatility and unique chemical properties make it a promising candidate for further research and development in the field of pharmaceuticals.

InChI:InChI=1/C8H7N3S/c9-8-11-5-7(12-8)6-1-3-10-4-2-6/h1-5H,(H2,9,11)

Upstream product

• 1122-54-9 methyl (4-pyridyl) ketone 
• 17356-08-0 thiourea 
• 53289-47-7 2-chloro-1-pyridin-4-yl-ethanone 
• 6221-13-2 4-(bromoacetyl)pyridine 
• 5349-17-7 4-bromoacetylpyridine hydrobromide 
• 1701-69-5 1-(4-pyridyl)-1-propanone 

Downstream Products

• 692870-64-7 2-(2-fluorophenyl)-N-(4-pyridin-4-yl-thiazol-2-yl)acetamide 
• 1187669-22-2 N-(3-methylbenzyl)-4-(4-pyridinyl)-1,3-thiazol-2-amine 
• 393839-09-3 4-methoxy-N-[4-(4-pyridinyl)-1,3-thiazol-2-yl]benzamide 
• 476625-88-4 N-[4-(4-pyridinyl)-1,3-thiazol-2-yl]benzamide 
• 476631-30-8 3-methyl-N-[4-(4-pyridinyl)-1,3-thiazol-2-yl]benzamide 
• 476631-28-4 4-methyl-N-[4-(4-pyridinyl)-1,3-thiazol-2-yl]benzamide 
• 1328052-08-9 1-phenyl-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342277-11-5 1-(4-fluorophenyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342276-58-7 1-benzyl-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342276-63-4 1-(4-chlorobenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342276-92-9 1-(3-fluorobenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342276-85-0 (R)-1-(1-phenylethyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342276-89-4 (S)-1-(1-phenylethyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea 
• 1342277-18-2 phenyl 4-(pyridin-4-yl)thiazol-2-ylcarbamate 

Relevant articles and documents

4-(Pyridin-4-yl)thiazol-2-amine as an efficient non-toxic inhibitor for mild steel in hydrochloric acid solutions

A novel eco-friendly corrosion inhibitor, namely, 4-(pyridin-4-yl)thiazol-2-amine (PTA), was synthesized and evaluated as a corrosion inhibitor for mild steel in 1 M HCl solution. Its inhibition effect against mild steel corrosion was investigated via weight loss methods, electrochemical measurements, and surface analyses. The experimental results showed that PTA is an effective corrosion inhibitor for mild steel in an acid medium, and the maximum inhibition efficiency reached 96.06% at 0.2 mM concentration. Polarization studies showed that PTA acted as a mixed inhibitor. The sorption behavior on the steel surface complies with the Langmuir adsorption isotherm, exhibiting both physisorption and chemisorption. The constitution and characteristic of the protective layer on the steel surface were verified using scanning electron microscopy (SEM)/energy-dispersive X-ray spectroscopy (EDX) and UV-Vis spectroscopy. Quantum chemistry calculations were used to study the relationship between the inhibition efficiency and molecular structure of the inhibitor.

Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors

A series of urea-based ROCK2 inhibitors were design and synthesized. The inhibitory activity on ROCK2 was screened by enzyme-linked immunosorbent assay (ELISA). The study results showed that the urea derivatives exhibited certain ROCK2 inhibitory activity. The most potent compound 10p showed ROCK2 inhibitory activity with the IC50?value of 0.03?μM. A preliminary structure-activity relationship was then summarized. The molecular docking studies showed that further optimization needs to conduct to obtain more potent ROCK inhibitors.

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.